Hospital
Sharp Coronado Hospital and Healthcare Center
Sharp Coronado Hospital and Healthcare Center was paid $34.30M by Medicaid between Jan 2018 and Dec 2024, across 145 billing codes. Its largest line is 99283, emergency room visit (moderate) — 27% of everything it billed.
33Billing provider infoSHARP CORONADO HOSPITAL AND HEALTHCARE CENTER
CORONADO, CA 92118
CORONADO, CA 92118
33aNPI1154304475assigned 11/21/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$34.30M
24GClaims310,070
24DCodes billed145
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#85 of 410
Median peer was paid$6.90M
This provider vs. median5.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 30,357 | $2.07M | |
| 2019 | 31,937 | $2.60M | |
| 2020 | 31,103 | $2.91M | |
| 2021 | 46,452 | $4.52M | |
| 2022 | 63,332 | $7.30M | |
| 2023 | 65,228 | $8.22M | |
| 2024incomplete | 41,661 | $6.68M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 19,356 | 17,874 | $9.19M |
| 0450 | Emergency room services | 19% | 20,612 | 19,081 | $6.37M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.3% | 3,715 | 3,634 | $2.86M |
| 99499 | 7.3% | 7,779 | 6,577 | $2.51M | |
| 99199 | Unlisted special service, procedure or report | 3.5% | 1,585 | 1,399 | $1.20M |
| 80053 | Comprehensive metabolic panel | 3.2% | 24,893 | 23,092 | $1.11M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.0% | 3,437 | 3,341 | $1.01M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.5% | 12,487 | 11,572 | $854K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.4% | 6,807 | 6,283 | $810K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.1% | 2,400 | 2,178 | $734K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 8,868 | 8,300 | $733K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 27,098 | 25,035 | $545K |
133 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 1,099 | $503K |
| 71045 | Radiologic examination, chest; single view | 1.4% | 9,417 | $484K |
| 99285 | Emergency room visit (most serious) | 1.4% | 1,180 | $478K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,070 | $332K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 7,220 | $280K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 446 | $262K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 647 | $240K |
| 0360 | <1% | 209 | $230K | |
| 83690 | <1% | 10,098 | $227K | |
| 84484 | <1% | 7,694 | $225K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,467 | $223K |
| 81001 | <1% | 13,777 | $208K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,757 | $196K |
| Z7502 | <1% | 4,265 | $157K | |
| 87040 | <1% | 1,727 | $134K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,396 | $133K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,312 | $110K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,615 | $97K |
| 82962 | <1% | 5,030 | $93K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,605 | $92K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,155 | $85K |
| 80305 | <1% | 1,172 | $80K | |
| 84703 | <1% | 5,844 | $77K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 456 | $75K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 591 | $67K |
| 83735 | <1% | 3,572 | $62K | |
| 85610 | <1% | 4,098 | $60K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,147 | $55K |
| 84702 | <1% | 1,668 | $55K | |
| 82077 | <1% | 1,343 | $48K | |
| 76830 | Ultrasound, transvaginal | <1% | 366 | $47K |
| 73030 | <1% | 576 | $42K | |
| 73562 | <1% | 736 | $42K | |
| 0710 | <1% | 195 | $42K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,561 | $41K |
| 73630 | <1% | 661 | $41K | |
| 83880 | <1% | 1,653 | $41K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 644 | $39K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,095 | $34K |
| 83605 | <1% | 2,252 | $34K | |
| 87081 | <1% | 1,332 | $34K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 233 | $27K |
| 85379 | <1% | 1,070 | $27K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 536 | $26K |
| 85730 | <1% | 2,154 | $24K | |
| 93971 | <1% | 101 | $23K | |
| 73610 | <1% | 314 | $21K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 619 | $21K |
| 87186 | <1% | 1,545 | $20K | |
| 87631 | <1% | 429 | $18K | |
| 70496 | <1% | 39 | $18K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,401 | $17K |
| 76801 | <1% | 120 | $17K | |
| 73130 | <1% | 261 | $17K | |
| 70498 | <1% | 40 | $17K | |
| 87077 | <1% | 1,653 | $15K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,558 | $14K |
| 70486 | <1% | 28 | $14K | |
| 80143 | <1% | 314 | $13K | |
| 80179 | <1% | 293 | $11K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 66 | $11K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 24 | $11K |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,835 | $9K |
| 81003 | <1% | 1,002 | $9K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,725 | $8K |
| 86900 | <1% | 294 | $8K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 70 | $8K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,222 | $8K |
| 72100 | <1% | 104 | $7K | |
| 72131 | <1% | 24 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,716 | $6K |
| 86140 | <1% | 527 | $6K | |
| 86901 | <1% | 294 | $6K | |
| 84145 | <1% | 273 | $5K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 195 | $5K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,606 | $5K |
| 82550 | <1% | 302 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,530 | $5K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 161 | $5K |
| 97139 | <1% | 220 | $5K | |
| 71250 | <1% | 25 | $5K | |
| 0258 | <1% | 566 | $5K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 53 | $4K |
| 96376 | <1% | 113 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 787 | $3K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 338 | $3K |
| 90715 | <1% | 130 | $3K | |
| 73110 | <1% | 29 | $3K | |
| 87510 | <1% | 153 | $2K | |
| 87660 | <1% | 153 | $2K | |
| 87480 | <1% | 153 | $2K | |
| 73080 | <1% | 25 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 176 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,155 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 609 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,102 | $2K |
| 74018 | <1% | 40 | $2K | |
| 80061 | Lipid panel | <1% | 590 | $2K |
| 84439 | <1% | 221 | $2K | |
| 85652 | <1% | 246 | $2K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 111 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 533 | $1K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 903 | $1K |
| 87070 | <1% | 66 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,140 | $1K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 797 | $972.29 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 544 | $918.72 |
| 88304 | <1% | 37 | $875.59 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 89 | $869.69 |
| 82553 | <1% | 32 | $854.05 | |
| 85027 | <1% | 101 | $678.66 | |
| 82248 | <1% | 43 | $503.87 | |
| 73502 | <1% | 15 | $471.00 | |
| 87205 | <1% | 55 | $371.56 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 351 | $347.46 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 42 | $328.96 |
| 82728 | <1% | 31 | $323.28 | |
| 83615 | <1% | 27 | $314.05 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 13 | $286.71 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 92 | $245.23 |
| 86850 | <1% | 13 | $222.76 | |
| 82150 | <1% | 13 | $216.62 | |
| J3490 | Unclassified drugs | <1% | 13 | $154.98 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 46 | $150.46 |
| 82140 | <1% | 13 | $132.20 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 13 | $97.29 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 12 | $66.79 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 41 | $59.18 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 38 | $49.76 |
| 83540 | <1% | 13 | $40.93 | |
| 82607 | <1% | 12 | $21.03 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 50 | $0.01 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTONE, SUSAN (CEO)
Parent organizationSHARP CORONADO HOSPITAL AND HEALTHCARE CENTER
| Provider | Location | Paid |
|---|---|---|
| Grace Reliant Healthcare, LLC | Jackson, MO | $22.04M |
| Sharp Coronado Hospital and Healthcare Center | Coronado, CA | $24K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.